Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAU-SED vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Mild to moderate hypertension,Management of psychotic disorders (off-label)
Hypertension
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Extensively metabolized in the liver via ester hydrolysis; major metabolite is trimethoxybenzoic acid; not fully characterized in humans.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
96% bound, primarily to albumin and alpha-1-acid glycoprotein
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
8-10 L/kg; clinical meaning: extensive tissue distribution, high affinity for adipose tissue and brain
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 40-50% (first-pass metabolism); Intramuscular: 100% (complete absorption)
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-60 m L/min), reduce dose by 50%. No adjustment needed for Cr Cl >60 m L/min.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). For moderate impairment (Child-Pugh Class B), reduce dose by 50% and monitor for excessive sedation. No adjustment for mild (Child-Pugh Class A).
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not recommended due to lack of safety and efficacy data. Avoid use in children.
Not established; avoid use in children.
Initiate with 0.1 mg orally once daily; titrate slowly based on response and tolerability. Monitor for orthostatic hypotension and sedation.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
Reserpine may increase the risk of suicide; patients should be monitored for depression. It should not be used in patients with a history of mental depression.
None
May cause severe depression, especially in patients with psychiatric history; may cause bradycardia, electrolyte imbalance, and gastrointestinal effects; caution in patients with peptic ulcer disease or gallstones due to increased gastric acid secretion.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
History of mental depression (especially suicidal tendencies), active peptic ulcer, ulcerative colitis, concurrent electroconvulsive therapy (ECT), hypersensitivity to reserpine or rauwolfia alkaloids.
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce) as rauwolfia alkaloids can potentiate hypertensive crises. Limit caffeine intake. High-fiber diets may reduce absorption separate doses.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
Reserpine crosses placenta. First trimester: Increased risk of congenital malformations (cardiac defects, CNS anomalies) in animal studies; human data limited but risk considered elevated. Second/third trimesters: Risk of neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to catecholamine depletion. Avoid use throughout pregnancy unless essential.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Reserpine is excreted into breast milk. M/P ratio not reported. Potential for infant effects: nasal congestion, bradycardia, hypotonia. Use is contraindicated due to possible severe adverse effects in the nursing infant.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Dose should be kept as low as possible. Due to increased plasma volume in pregnancy, monitor clinical response; no specific dose adjustment recommendations. Consider alternative antihypertensives with better safety profile.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
RAU-SED (rauwolfia serpentina) is an antihypertensive and antipsychotic alkaloid. Onset of action is slow (2-3 weeks) for hypertension. Monitor for bradycardia, nasal congestion, and depression. Do not use with MAOIs or electroconvulsive therapy. Taper to avoid withdrawal hypertension.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not stop suddenly as this may cause severe hypertension.,May cause drowsiness, dizziness, or nasal congestion; avoid driving if affected.,Report signs of depression, nightmares, or extrapyramidal symptoms (muscle stiffness, tremors).,Avoid alcohol and over-the-counter cold medications containing decongestants.,Rise slowly from sitting or lying to minimize postural hypotension.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAU-SED vs ALDORIL 25, answered by our medical review team.
RAU-SED is a Antihypertensive that works by Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAU-SED and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAU-SED is: Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAU-SED and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAU-SED is classified as Category C. Reserpine crosses placenta. First trimester: Increased risk of congenital malformations (cardiac defects, CNS anomalies) in animal studies; human data limited but risk considered e. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.